Short answer
Emergent BioSolutions Inc. (EBS) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $110M (down 52.4% year over year) with net income of −$33M.
Q3 2026 key financials · XBRL
- Revenue
- $110M
- −52.4% YoY · −53.1% QoQ
- Net income
- −$33M
- −163.9% YoY · +81.9% QoQ
- Operating margin
- -33.9%
- EPS (diluted)
- −$0.64
- −171.1% YoY · +81.3% QoQ
Source: XBRL data from the Emergent BioSolutions Inc. (EBS) Q3 2026 10-Q on SEC EDGAR. USD.
Emergent BioSolutions Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $110.0M, down 52% YoY from $231.1M
- Gross margin 14% vs 54% YoY, operating loss $37.3M vs income $76.5M
- Best segment Anthrax MCM, revenue $25.1M, up $23.7M; worst Smallpox MCM, $26.7M, down 68%
- Cash and equivalents $175.7M vs $205.4M at December 31; operating cash flow $122.4M
- Debt repurchases $75.0M principal, $68.1M cash; management expects continued quarterly variability and cites NARCAN pricing and volume pressure
Risk Factors
- Third-party manufacturing: FDA noncompliance could halt sole-source production and interrupt customer supply
- NARCAN competition: Teva, Padagis and Amneal generics could erode sales through lower-priced or free alternatives
- Restructuring plan: August 5, 2026 workforce reductions and wet-laboratory closures may disrupt operations
- Political and social pressures: USG preference for U.S.-made products may reduce Winnipeg facility purchases
- Restructuring compliance: Workforce reductions may trigger wrongful-termination or discrimination claims under local labor laws
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Emergent BioSolutions Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.